2487 Stock Overview An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cutia Therapeutics Competitors Price History & Performance
Summary of share price highs, lows and changes for Cutia Therapeutics Historical stock prices Current Share Price HK$6.38 52 Week High HK$18.26 52 Week Low HK$5.57 Beta 0 1 Month Change -17.78% 3 Month Change -61.66% 1 Year Change -41.89% 3 Year Change n/a 5 Year Change n/a Change since IPO -70.93%
Recent News & Updates
New minor risk - Shareholder dilution Dec 06
Cupia Therapeutics Announces Phase II Clinical Trial of CU-20401 (Recombinant Mutant Collinant Mutant Collinase) for Submental Adipose Accumulation Reaches Primary Endpoint Nov 29
Cutia Therapeutics Announces Results of Phase III Clinical Trial of CU-40102 (Topical Finasteride Spray) and CU-30101 Nov 28
Cutia Therapeutics Announces CU-10201 (Topical 4% Minocycline Foam) Obtains Marketing Approval by the National Medical Products Administration Nov 12
Now 24% undervalued Nov 08
CFO & Executive Director recently bought HK$422k worth of stock Oct 15 See more updates
New minor risk - Shareholder dilution Dec 06
Cupia Therapeutics Announces Phase II Clinical Trial of CU-20401 (Recombinant Mutant Collinant Mutant Collinase) for Submental Adipose Accumulation Reaches Primary Endpoint Nov 29
Cutia Therapeutics Announces Results of Phase III Clinical Trial of CU-40102 (Topical Finasteride Spray) and CU-30101 Nov 28
Cutia Therapeutics Announces CU-10201 (Topical 4% Minocycline Foam) Obtains Marketing Approval by the National Medical Products Administration Nov 12
Now 24% undervalued Nov 08
CFO & Executive Director recently bought HK$422k worth of stock Oct 15
CFO & Executive Director recently bought HK$460k worth of stock Oct 09
Cutia Therapeutics Announces All Enroll Patients Completes Phase II Clinical Trial of CU-20401 Sep 30
Cutia Therapeutics announces First Patient Enrolled in the Phase I Clinical Trial of CU-10101 (Topical Novel Small Molecule Agent)For Atopic Dermatitis Sep 27
Now 21% overvalued after recent price rise Sep 20
First half 2024 earnings released: CN¥0.66 loss per share (vs CN¥15.84 loss in 1H 2023) Sep 04
Does Cutia Therapeutics (HKG:2487) Have A Healthy Balance Sheet? Aug 30
Cutia Therapeutics Announces Results of Phase III Clinical Trial of Cu-40102 (Topical Finasteride Spray) in the PRC Accepted for E-Poster Presentation Aug 29
Cutia Therapeutics to Report First Half, 2024 Results on Aug 29, 2024 Aug 20
Now 45% undervalued after recent price drop Aug 01
Cutia Therapeutics Announces Drug Marketing Authorization Application for CU-30101 (Localized Topical Lidocaine and Tetracaine Cream) Accepted by the National Medical Products Administration Aug 01
New minor risk - Share price stability Jul 31
Cutia Therapeutics Announces Results of Phase III Clinical Trial of Cu-10201 (Topical 4% Minocycline Foam) in the PRC Published Online in the Journal of the European Academy of Dermatology and Venereology Jul 30
Cutia Therapeutics (SEHK:2487) commences an Equity Buyback for 30,473,862 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2024. Jul 17 Cutia Therapeutics (SEHK:2487) commences an Equity Buyback for 30,473,862 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2024. Jul 16
Now 43% undervalued after recent price drop Jul 02 Cutia Therapeutics Announces Last Patient Enrollment in the Phase II Clinical Trial of Cu-20401
Now 23% undervalued after recent price drop Jun 24
A Look At The Intrinsic Value Of Cutia Therapeutics (HKG:2487) Jun 03
Cutia Therapeutics Announces Investigational New Drug Application of CU-10101 for Atopic Dermatitis Approved by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China May 30
Cutia Therapeutics Submits New Drug Application for Cu-40102 (Topical Finasteride Spray) in Hong Kong, PRC May 01 Cutia Therapeutics, Annual General Meeting, Jun 05, 2024 Apr 28
Analysts Are Betting On Cutia Therapeutics (HKG:2487) With A Big Upgrade This Week Apr 08
Consensus revenue estimates increase by 40%, EPS downgraded Apr 03
No longer forecast to breakeven Apr 02
New minor risk - Profitability Apr 01
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 28
Cutia Therapeutics Announces the Investigational New Drug Application of CU-10101 (Topical Novel Small Molecule Agent) for the Treatment of Mild to Moderate Atopic Dermatitis Accepted by the Center for Drug Evaluation of the National Medical Products Administration Mar 27
Cutia Therapeutics to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
Consensus revenue estimates increase by 21% Mar 06
Cutia Therapeutics Announces Completion of Phase I Clinical Trial of CU-20401 Feb 28
Less than half of directors are independent Feb 22
Cutia Therapeutics Announces New Drug Application for CU-40102 (Topical Finasteride Spray) Accepted by the National Medical Products Administration Jan 31
Forecast to breakeven in 2026 Dec 31
Cutia Therapeutics Announces Results of Phase III Clinical Trials of CU-40102 (Topical Finasteride Spray) and CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China Dec 11
Cutia Therapeutics Announces Phase I Clinical Trial of Cu-20401 Abdominal Adipose Accumulation Completes Database Lock Nov 29
Cutia Therapeutics Announces Phase I Clinical Trial of Cu-20401 Abdominal Adipose Accumulation Completes Database Lock Nov 28
Cutia Therapeutics Announces Phase I Clinical Trial of CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment) in China Reached Primary Endpoint Nov 03
Cutia Therapeutics Announces All Enrolled Patients Completes Phase I Clinical Trial of CU-20401 Oct 26
Cutia Therapeutics Announces New Drug Application for CU-10201 (Topical 4% Minocycline Foam) Accepted by the National Medical Products Administration Sep 28
First half 2023 earnings released Sep 25
New minor risk - Profitability Sep 08
Cutia Therapeutics Announces Registrational Phase III Clinical Trial of the Group's CU-40102 Conducted in China for the Treatment of Androgenetic Alopecia Reached Primary Endpoint Sep 08 Cutia Therapeutics Announces Phase I Clinical Trial of CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment) Completed Database Lock
Cutia Therapeutics Completes Phase Iii Clinical Trial of Cu-30101 Aug 24
Cutia Therapeutics to Report First Half, 2023 Results on Aug 29, 2023 Aug 18
Cutia Therapeutics Announces CU-10201 (Topical 4% Minocycline Foam) Granted Priority Review Designation by the Center for Drug Evaluation of the National Medical Products Administration Aug 11
Less than half of directors are independent Jun 12 Shareholder Returns 2487 HK Biotechs HK Market 7D -6.5% -0.6% 1.1% 1Y -41.9% -13.5% 17.6%
See full shareholder returns
Return vs Market: 2487 underperformed the Hong Kong Market which returned 17.6% over the past year.
Price Volatility Is 2487's price volatile compared to industry and market? 2487 volatility 2487 Average Weekly Movement 8.6% Biotechs Industry Average Movement 10.6% Market Average Movement 8.5% 10% most volatile stocks in HK Market 17.8% 10% least volatile stocks in HK Market 3.9%
Stable Share Price: 2487 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2487's weekly volatility (9%) has been stable over the past year.
About the Company Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company’s products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment; CU-10201, a topical 4% minocycline foam, approved for acne vulgaris treatment; and CU-10101, a topical novel small molecule agent, and a non-hormonal and small molecule drug for the treatment of mild to moderate atopic dermatitis.
Show more Cutia Therapeutics Fundamentals Summary How do Cutia Therapeutics's earnings and revenue compare to its market cap? 2487 fundamental statistics Market cap HK$2.03b Earnings (TTM ) -HK$557.48m Revenue (TTM ) HK$211.42m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2487 income statement (TTM ) Revenue CN¥198.86m Cost of Revenue CN¥98.77m Gross Profit CN¥100.08m Other Expenses CN¥624.43m Earnings -CN¥524.34m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -1.65 Gross Margin 50.33% Net Profit Margin -263.68% Debt/Equity Ratio 17.7%
How did 2487 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 04:37 End of Day Share Price 2024/12/30 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cutia Therapeutics is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Zhuonan Xu China International Capital Corporation Limited Hangci Zheng China International Capital Corporation Limited Yifan Du Citic Securities Co., Ltd.
Show 3 more analysts 
